Securities Registration: Employee Benefit Plan (s-8)
November 19 2020 - 5:23PM
Edgar (US Regulatory)
As filed with the Securities and Exchange
Commission on November 19, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933
Novartis AG
(Exact name of registrant as specified in
its charter)
Switzerland
|
|
N/A
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
Lichtstrasse 35
CH-4056 Basel, Switzerland
(Address of principal executive offices)
Novartis AG Long Term Incentive Plan
Novartis AG Deferred Share Bonus Plan
Novartis Corporation 2011 Stock Incentive
Plan for North American Employees
(Full title of the plan)
Shannon Thyme Klinger
Chief Legal Officer
Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland
(Name and address of agent for service)
+41 61 324 1111
(Telephone number, including area code,
of agent for service)
Copy to:
G. Scott Lesmes
David M. Lynn
Morrison & Foerster LLP
2000 Pennsylvania Avenue NW
Washington, D.C. 20006
(202)
887-1563
Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an
emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x
|
|
Accelerated filer ¨
|
|
Non-accelerated filer ¨
|
|
Smaller reporting company ¨
|
Emerging growth company ¨
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
CALCULATION OF REGISTRATION FEE
Title of Securities to be
Registered
|
|
Amount to be
Registered(2)
|
|
|
Proposed Maximum
Offering Price
Per Share(3)
|
|
Proposed Maximum
Aggregate Offering
Price(3)
|
|
Amount of
Registration
Fee (4)
|
Ordinary Shares of Novartis AG, nominal value CHF 0.50 per share (1)
|
|
|
10,000,000
|
|
|
$85.91
|
|
$859,100,000
|
|
$93,727.81
|
Ordinary Shares of Novartis AG, nominal value CHF 0.50 per share (1)
|
|
|
1,200,000
|
|
|
$85.91
|
|
$103,092,000
|
|
$11,247.34
|
Ordinary Shares of Novartis AG, nominal value CHF 0.50 per share (1)
|
|
|
41,000,000
|
|
|
$85.91
|
|
$3,522,310,000
|
|
$384,284.02
|
Total
|
|
|
52,200,000
|
|
|
|
|
|
|
$489,259.17
|
(1)
The ordinary shares of Novartis AG, nominal value CHF 0.50 per share (“Novartis Shares”) will be represented
by American Depositary Shares of Novartis AG (“Novartis ADSs”), each of which currently represents one Novartis
Share. A separate registration statement on Form F-6 (333-198623) has been filed with the Securities and Exchange Commission (the
“Commission”) on September 8, 2014 for the registration of Novartis ADSs evidenced by American Depositary Receipts
issuable upon deposit of the Novartis Shares.
(2) The aggregate number of Novartis Shares being registered
represents the sum of 10,000,000 Novartis Shares being registered under the Novartis AG Long Term Incentive Plan, 1,200,000 Novartis
Shares being registered under the Novartis AG Deferred Share Bonus Plan and 41,000,000 Novartis Shares being registered under
the Novartis Corporation 2011 Stock Incentive Plan for North American Employees. The Novartis Shares are represented by a like
number of Novartis ADSs.
(3) Pursuant to Rule 416 of the Securities Act of 1933, as amended
(the “Securities Act”), the amount being registered also includes an indeterminate number of Novartis Shares,
which may be issuable under the plans as a result of variations in share capital, share splits, share dividends or similar transactions.
(4)
Estimated pursuant to Rule 457(c) under the Securities Act solely for the purpose of computing the registration fee, based
upon the average of the high and low price for the Novartis ADSs on the New York Stock Exchange on November 13, 2020.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a)
PROSPECTUS
The information required by Item 1 and Item
2 of Part I of Form S-8 is omitted from this filing in accordance with Rule 428 under the Securities Act and the introductory note
to Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants in the
plans covered by this Registration Statement as required by Rule 428(b)(1).
PART II
INFORMATION REQUIRED IN THE REGISTRATION
STATEMENT
|
Item 3.
|
INCORPORATION OF DOCUMENTS BY REFERENCE
|
The
following documents previously filed with or furnished to the Commission by Novartis AG (the “Registrant”)
are incorporated by reference herein and shall be deemed to be part hereof:
(a) Registrant’s Annual Report on Form 20-F for the year ended December 31, 2019, filed with the Commission on January 29, 2020;
(b) The descriptions of the Novartis Shares contained in Items 6.C, 9.A and 10.B of the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2019, filed with the Commission on January 29, 2020; and
(c) All other reports filed or furnished
pursuant to Section 13(a) or 15(d) of the Exchange Act since December 31, 2019, including any reports on Form 6-K, including without
limitation its Reports on Form 6-K furnished on April
28, 2020 relating to the First Quarter Financial Report and Condensed Interim Financial Report – Supplementary Data;
July
21, 2020 relating to the Second Quarter and Half Year Financial Report and Condensed Interim Financial Report – Supplementary
Data; and October
27, 2020 relating to the Third Quarter Financial Report and Condensed Interim Financial Report – Supplementary Data.
All documents filed with the Commission
by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934 (the “Exchange
Act”) and reports on Form 6-K furnished to the Commission subsequent to the date hereof and prior to the filing of a
post-effective amendment indicating that all securities offered herein have been sold or which deregisters all securities then
remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from
the date such reports are filed or furnished, as applicable.
Any statement contained herein or in a document
incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes hereof
or of the related prospectus to the extent that a statement contained herein or in any other subsequently filed document which
is also incorporated or deemed to be incorporated herein modifies or supersedes such statement. Any such statement so modified
or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
|
Item 4.
|
DESCRIPTION OF SECURITIES
|
Not applicable.
|
Item 5.
|
INTERESTS OF NAMED EXPERTS AND COUNSEL
|
Not applicable.
|
Item 6.
|
INDEMNIFICATION OF DIRECTORS AND OFFICERS
|
Under Swiss law, directors and senior officers
acting in violation of their statutory duties—whether dealing with bona fide third parties or performing any other acts on
behalf of the corporation—may become liable to the corporation, its shareholders and (in bankruptcy) its creditors for damages.
The directors’ liability is joint and several but only to the extent the damage is attributable to each director based on
willful or negligent violation of duty. If the board of directors lawfully delegated the power to carry out day-to-day management
to a different corporate body, such as the executive committee, the board of directors is not vicariously liable for the acts of
the members of the executive committee. Instead, the directors can be held liable for their failure to properly select, instruct
or supervise the executive committee members. If directors and officers enter into a transaction on behalf of the corporation with
bona fide third parties in violation of their statutory duties, the transaction is nevertheless valid as long as it is not excluded
by the corporation's business purpose.
Under Swiss law, a corporation may indemnify
a director or officer of the corporation against losses and expenses (unless arising from his gross negligence or willful misconduct),
including attorney's fees, judgments, fines and settlement amounts actually and reasonably incurred in a civil or criminal action,
suit or proceeding by reason of having been the representative of or serving at the request of the corporation.
Registrant’s
articles of incorporation do not contain provisions regarding the indemnification
of directors and officers but according to general principles of Swiss employment law, an employer may, under certain circumstances,
be required to indemnify an employee against losses and expenses incurred by him or her in the execution of his or her duties under
the employment agreement, unless the losses and expenses arise from the employee’s gross negligence or willful misconduct.
Registrant currently maintains directors’
and officers’ insurance for its directors and officers as well as officers and directors of certain of its subsidiaries.
|
Item 7.
|
EXEMPTION FROM REGISTRATION CLAIMED
|
Not Applicable.
Exhibit
Number
|
|
Exhibit
|
4.1
|
|
Articles of Incorporation of Novartis AG, as amended February 28, 2020 (English translation)
|
|
|
|
4.2
|
|
Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG, effective February 1, 2020
|
|
|
|
4.3
|
|
Amended and Restated Deposit Agreement, dated as of May 11, 2000 among Novartis AG, JPMorgan Chase Bank (fka Morgan Guaranty Trust Company of New York), as depositary, and all holders from time to time of ADRs issued thereunder (incorporated by reference to Exhibit (a)(1) to Post-Effective Amendment No. 1 to Novartis AG’s registration statement on Form F-6 (File No. 333-11758) as filed with the Commission on September 8, 2000)
|
|
|
|
4.4
|
|
Amendment No. 1 to the Amended and Restated Deposit Agreement (incorporated by reference to Exhibit (a)(2) to Post-Effective Amendment No. 1 to Novartis AG’s registration statement on Form F-6 (File No. 333-11758) as filed with the Commission on September 8, 2000)
|
|
|
|
4.5
|
|
Amendment No. 2 to the Amended and Restated Deposit Agreement (incorporated by reference to Exhibit (a)(3) to Novartis AG’s registration statement on Form F-6 (File No. 333-13446) as filed with the Commission on May 7, 2001)
|
|
|
|
4.6
|
|
Restricted Issuance Agreement, dated as of January 11, 2002, among Novartis AG, JPMorgan Chase Bank, as depositary, and all holders from time to time of ADRs issued thereunder (incorporated by reference to Exhibit 4 to Novartis AG’s registration statement on Form F-3 (File No. 333-81862) as filed with the Commission on January 31, 2002)
|
|
|
|
4.7
|
|
Letter Agreement, dated December 14, 2007, between Novartis AG and JPMorgan Chase Bank, as depositary (incorporated by reference to Exhibit 2.4 to Novartis AG’s Annual Report on Form 20-F for the year ended on December 31, 2007 as filed with the Commission on January 28, 2008)
|
|
|
|
4.8
|
|
Form of American Depositary Receipt (incorporated by reference to Exhibit (a)(7) to the Registration Statement on Form F-6 (File No. 333-198623) as filed with the Commission on September 8, 2014)
|
|
|
|
4.9
|
|
Novartis AG Long Term Incentive Plan, adopted on January 22, 2014, and amended and restated on October 22, 2020
|
|
|
|
4.10
|
|
Novartis AG Deferred Share Bonus Plan, adopted on January 22, 2014, and amended and restated on October 22, 2020
|
|
|
|
4.11
|
|
Novartis Corporation 2011 Stock Incentive Plan for North American Employees, adopted on November 11, 2010, and amended and restated on October 24, 2020
|
|
|
|
5.1
|
|
Opinion of Bär & Karrer AG
|
|
|
|
23.1
|
|
Consent of Independent Auditors - PricewaterhouseCoopers AG
|
|
|
|
24
|
|
Powers of Attorney (included on signature pages)
|
(a) The undersigned Registrant hereby undertakes:
(1) to file, during any period in which offers or
sales are being made, a post-effective amendment to this Registration Statement:
(i) to include any prospectus
required by Section 10(a)(3) of the Securities Act;
(ii) to reflect in the prospectus any facts or events
arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually
or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement (notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would
not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be
reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation
of Registration Fee” table in this Registration Statement); and
(iii) to include any material information with respect
to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in
the Registration Statement;
provided,
however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section
13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement;
(2) that, for the purpose of determining any liability
under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof; and
(3) to remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at the termination of the offering.
(b)
The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing
of the Registrant’s Annual Report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable,
each filing of an employee benefit plan’s Annual Report pursuant to Section 15(d) of the Exchange Act) that is incorporated
by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under
the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing
provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing
on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
in Basel, Switzerland on November 19, 2020.
|
NOVARTIS AG
|
|
|
|
|
By:
|
/s/ Harry Kirsch
|
|
|
Name: Harry Kirsch
|
|
|
Title: Chief Financial Officer
|
|
|
|
|
By:
|
/s/ Shannon Thyme Klinger
|
|
|
Name: Shannon Thyme Klinger
|
|
|
Title: Chief Legal Officer
|
POWER OF ATTORNEY
KNOW
ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Harry Kirsch, Shannon Thyme
Klinger, Daniel Weiss, Christian Rehm, and each of them (with full power to each of them to act alone), his or her true and lawful
attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and
stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement
and to file the same with all exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission
granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act
and thing requisite and necessary to be done in and about the premises as fully to all intents and purposes as he or she might
or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their substitutes,
may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the
capacities indicated on this 19th day of November, 2020.
SIGNATURE
|
|
TITLE
|
|
|
|
/s/ Vasant Narasimhan, M.D.
|
|
Chief Executive Officer
|
Vasant Narasimhan, M.D.
|
|
(principal executive officer)
|
|
|
|
|
|
|
/s/ Harry Kirsch
|
|
Chief Financial Officer
|
Harry Kirsch
|
|
(principal financial and accounting officer)
|
|
|
|
|
|
|
/s/ Joerg Reinhardt, Ph.D.
|
|
Chairman of the Board of Directors
|
Joerg Reinhardt, Ph.D.
|
|
|
|
|
|
|
|
|
/s/ Enrico Vanni, Ph.D.
|
|
Vice-Chairman of the Board of Directors
|
Enrico Vanni, Ph.D.
|
|
|
|
|
|
|
|
|
/s/ Nancy C. Andrews, M.D., Ph.D.
|
|
Director
|
Nancy C. Andrews, M.D. Ph.D.
|
|
|
|
|
|
|
|
|
/s/ Ton Buechner
|
|
Director
|
Ton Buechner
|
|
|
|
|
|
|
|
|
/s/ Patrice Bula
|
|
Director
|
Patrice Bula
|
|
|
|
|
|
|
|
|
/s/ Srikant Datar, Ph.D.
|
|
Director
|
Srikant Datar, Ph.D.
|
|
|
|
|
|
|
|
|
/s/ Elizabeth Doherty
|
|
Director
|
Elizabeth Doherty
|
|
|
|
|
|
|
|
|
/s/ Ann Fudge
|
|
Director
|
Ann Fudge
|
|
|
|
|
|
|
|
|
/s/ Bridgette Heller
|
|
Director
|
Bridgette Heller
|
|
|
|
|
|
|
|
|
/s/ Frans van Houten
|
|
Director
|
Frans van Houten
|
|
|
|
|
|
|
|
|
/s/ Simon Moroney, D.Phil.
|
|
Director
|
Simon Moroney, D.Phil.
|
|
|
|
|
|
|
|
|
/s/ Andreas von Planta, Ph.D.
|
|
Director
|
Andreas von Planta, Ph.D.
|
|
|
|
|
|
|
|
|
/s/ Charles L. Sawyers, M.D.
|
|
Director
|
Charles L. Sawyers, M.D.
|
|
|
|
|
|
|
|
|
/s/ William T. Winters
|
|
Director
|
William T. Winters
|
|
|
AUTHORIZED REPRESENTATIVE
Pursuant to the requirements of the Securities
Act of 1933, the undersigned certifies that it is the duly authorized United States representative of the Registrant and has duly
caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in East
Hanover, New Jersey on November 19, 2020.
|
/s/ David C. Hellmuth
|
|
David C. Hellmuth
|
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024